Industry Newsbiopharmam and aservierrare disease
Day One Biopharmaceuticals Accepts $2.5B Acquisition
5.2
Relevance Score
Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) said this week that France-based Servier will acquire the company for $2.5 billion, tendering all shares at $21.50 apiece. The offer represents a 68% premium to the $12.78 pre-announcement close and is expected to close in the second quarter, subject to customary closing conditions and shareholder approval.
Scoring Rationale
Official $2.5B acquisition announcement provides credible market insight, but limited AI/ML relevance constrains portal impact.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problemsFree Career Roadmaps8 PATHS
Step-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Data Analyst
Explore all career paths $95K
Data Scientist$130K
ML Engineer$155K
AI Engineer$160K
Data Engineer$140K
Analytics Eng.$140K
MLOps Engineer$160K
Quant Analyst$175K
Sources
- Read OriginalDay One (DAWN) Soars 100% on $2.5-Billion Mergerinsidermonkey.com
